Skip to main content
OpenTrials
Completed

NCT Number: NCT06683586

Brazilian Registry of Chronic Venous Disease - Risk Factors, Comorbidities, Clinical and Surgical Treatment

Chronic venous disease (CVD) is a widespread and challenging condition globally, encompassing the full range of anatomical and functional abnormalities in the venous system of the lower extremities. It is characterized by symptoms such as edema, skin changes, and venous ulcers, primarily caused by venous insufficiency with resulting reflux.

CVD significantly impacts quality of life and imposes a considerable socioeconomic burden. Lifestyle factors play a critical role in the risk of developing CVD. In recent years, average body mass index (BMI) values have risen in Western countries, with obesity recognized as a major risk factor for CVD. Additional factors, including smoking, physical inactivity, and hypertension, are also linked to an increased risk of CVD and chronic venous insufficiency.

There is a lack of recent Brazilian data on the prevalence and epidemiological characteristics of CVD, highlighting the need for this study. This research aims to gather national data on risk factors, associated comorbidities, and treatment types in Brazilian patients with CVD. The primary goal is to describe the clinical and epidemiological profile of CVD in the Brazilian population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital das Clinicas HCFMUSP

São Paulo, 0543000, Brazil

About this study

Chronic venous disease (CVD), also known as chronic venous insufficiency in its advanced stages, is marked by dysfunction in the peripheral venous system of the lower extremities, often due to venous flow obstruction or reflux. Affecting approximately 25-45% of women and 10-40% of men, CVD significantly increases public health expenditures. While the exact mechanisms remain unclear, evidence suggests that CVD is multifactorial, involving heightened inflammation, valvular incompetence, and calf muscle dysfunction, all contributing to impaired venous return and elevated venous pressure.

Common symptoms include varicose veins, lower limb edema, leg discomfort, and heaviness. CVD is progressive and can advance from superficial vessel involvement, known as telangiectasia, to deep venous ulcers. Risk factors such as family history, prolonged standing, smoking, and obesity can contribute to its onset and progression. Conservative management focuses on lifestyle changes like exercise, weight control, limb elevation, and compression. Pharmacologic or surgical intervention may be necessary in advanced cases. Left untreated, CVD can severely impact patients' quality of life, hindering daily and work activities.

However, data on CVD prevalence in Brazil is limited, largely based on a single study by Maffei et al. in 1986, which found a 47.6% prevalence of varicose veins and a 3.6% prevalence of advanced CVD in 1,755 adults in Botucatu, São Paulo. To better serve Brazilian patients, further data on CVD prevalence, treatment, and risk factors is essential, aiding healthcare providers in optimizing patient care.

This study aims to characterize the clinical and epidemiological profile of Brazilian CVD patients through a multicenter, prospective observational study. Conducted across 10 centers nationwide, the study will recruit at least 65 patients per center over 12 weeks.

Quality of life will be assessed using the Aberdeen Varicose Vein Questionnaire (AVVQ), with lower scores indicating better quality of life. The Venous Clinical Severity Score (VCSS) will gauge CVD severity, with higher scores indicating greater disease severity. VCSS correlates with the CEAP classification system and ultrasound findings.

CVD diagnoses will be categorized using the CEAP classification:

C0: No signs of venous disease C1: Telangiectasia/reticular veins C2: Varicose veins (≥3 mm diameter) C3: Edema C4: Skin/subcutaneous changes due to CVD, subdivided into C4a (pigmentation/eczema), C4b (lipodermatosclerosis/Atrophie Blanche), and C4c (corona phlebectatica) C5: Healed venous ulcer C6: Active venous ulcer C6r: Recurrent active venous ulcer During exams, patients will undergo physical evaluation for CVD signs, followed by duplex ultrasound of superficial and perforating veins. These will be conducted in both standing and supine positions by qualified vascular specialists, alongside personal medical history, demographics, occupation, physical stress, and varicose vein symptoms.

The study will measure factors including:

Presence and location of saphenous vein insufficiency, reflux, and vein caliber Presence of perforating veins and reflux characteristics Presence of deep vein thrombosis and related complications The study also covers therapeutic procedures such as sclerotherapy, endovenous ablation, and surgical vein removal. Compression stockings and pharmacological treatments (e.g., diosmin + hesperidin, calcium dobesilate, troxerutin) will be documented, including usage frequency and duration.

Data on cardiovascular diseases, comorbidities (e.g., hypertension, diabetes, dyslipidemia), occupation, and family history of CVD will also be collected, providing comprehensive insights into the risk and impact of CVD on the Brazilian population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes diagnosed with chronic venous disease;
  • Age equal to or greater than 18 years;
  • Signature of the informed consent form.

Exclusion criteria

  • Non-agreement to participate in the study;
  • Pregnant women.

Treatment and study plan

Primary outcomes

  1. Classification of Venous Disease

    Time frame: Enrollment until Day 1

    Clinical Classification of Venous Disease system CEAP, clinical (C), etiological (E), anatomical (A) and pathological (P) classification as follows:

    C0 = No visible or palpable signs of venous disease; C1 = Telangiectasia or reticular veins; C2 = Varicose veins; distinguishable from reticular veins by a diameter ≥ 3 mm; C3 = Edema;

    C4 = Changes in skin and subcutaneous tissue secondary to CVD, subdivided into:

    C4a = Pigmentation or eczema; C4b = Lipodermatosclerosis or Atrophie Blanche; C4c = Corona phlebectatica; C5 = Cured venous ulcer; C6 = Active venous ulcer; C6r = Recurrent active venous ulcer.

Secondary outcomes

  1. Aberdeen Varicose Vein Questionnaire

    Time frame: Enrollment until 24 hours

    The quality of life assessment will be performed by the Aberdeen Varicose Vein Questionnaire (AVVQ), consisting of 13 questions totaling a score of 0 to 100 points.

  2. Severity of chronic venous disease

    Time frame: Enrollment until 24 hours

    The severity of chronic venous disease will be assessed by the Venous Clinical Severity Score (VCSS), which includes 10 clinical descriptors (pain, varicose veins, venous edema, skin pigmentation, inflammation, induration, number of active ulcers, duration of active ulceration, ulcer size and use of compressive therapy) scored from 0 to 3 (0 = absent; 1= mild; 2= moderate; 3= severe), which can total 30 points.10 VCSS has been shown to have a positive correlation with CEAP and reflux/obstruction assessed by ultrasound.

  3. Proportion of patients receiving treatment

    Time frame: Enrollment until 24 hours

    Proportion of patients with chronic venous disease who receive clinical and/or surgical treatment

  4. Proportion of associated comorbidities

    Time frame: Enrollment until 24 hours

    Proportion of associated comorbidities in patients with chronic venous disease.

  5. Risk factors rate

    Time frame: Enrollment until 24 hours

    Describe the risk factors for the occurrence of chronic venous disease.

Sponsors and collaborators

Lead sponsor

Vinícius C Quintão, MD, MSc, PhD

Other

Collaborators

  • University of Sao Paulo

Registry information

Official study title

Brazilian Registry of Chronic Venous Disease - Risk Factors, Comorbidities, Clinical and Surgical Treatment: BRAVO Study

Acronym: BRAVO

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 12, 2024
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.